Shaping Your Advocacy Strategy: Trends and drivers in today’s advocacy relations

By: MK&A


More than ever before, pharma has been seeking and is expected to integrate real-world perspectives and expertise of patients and patient groups across the entire drug development continuum. Earlier and greater engagement leads to more meaningful clinical endpoints, improved recruitment and retention rates, and a better understanding of treatment preferences, among a myriad of other benefits.

For many companies, however, uncertainty still exists around how to accomplish this. MK&A’s senior vice president, Ellen Coleman, MPH shares five specific tips companies can take to incorporate the patient voice within their clinical development process.

Challenge #1: Difficulty aligning internal teams on engagement strategy
 
Challenge #2: Clinical development ready for patient protocol input now
 
Challenge #3: What does it mean to really be patient centric?
 
Challenge #4: How does the patient advocacy function adapt to changes?
 
Challenge #5: Evaluating, prioritizing and centralizing stakeholder information



About the Author:

MK&A

MK&A (Mark Krueger & Associates, Inc.) is the leading consultant to pharmaceutical, biotech, device, and diagnostic companies around the world in their quests to deliver quality care through innovative and effective partnerships with patient, consumer, and professional groups. Through its unparalleled expertise, knowledge, and global on-the-ground networks, MK&A contributes to clients’ success by speeding the development, approval, and appropriate use of and access to their products and services at the same time it builds lasting and meaningful improvements to human health.

Back to Full Blog List